2025 Global 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 Global 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) market are Merck & Co., Pfizer Inc., Sanofi Pasteur, and GlaxoSmithKline plc (GSK). Merck leads the market with about a 78% share, being the largest manufacturer globally. Pfizer is recognized for extensive vaccine research, including PPSV23, and recently received significant regulatory approvals for pneumococcal conjugate vaccines. Sanofi Pasteur focuses on advancing global vaccination strategies, while GSK emphasizes equitable vaccine access worldwide.
Additionally, Chinese companies such as Walvax Biotechnology and Kangtai Bio are prominent regional players, expanding distribution especially in Asia. Walvax’s PPSV23 is distinguished as the first preservative-free vaccine of its kind and has been widely distributed in multiple countries, supported by robust clinical data. The global market continues growing rapidly, driven by rising pneumococcal disease awareness and vaccination programs led by these manufacturers across different regions, including North America, Europe, and Asia.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) market are Merck & Co., Pfizer Inc., Sanofi Pasteur, and GlaxoSmithKline plc (GSK). Merck leads the market with about a 78% share, being the largest manufacturer globally. Pfizer is recognized for extensive vaccine research, including PPSV23, and recently received significant regulatory approvals for pneumococcal conjugate vaccines. Sanofi Pasteur focuses on advancing global vaccination strategies, while GSK emphasizes equitable vaccine access worldwide.
Additionally, Chinese companies such as Walvax Biotechnology and Kangtai Bio are prominent regional players, expanding distribution especially in Asia. Walvax’s PPSV23 is distinguished as the first preservative-free vaccine of its kind and has been widely distributed in multiple countries, supported by robust clinical data. The global market continues growing rapidly, driven by rising pneumococcal disease awareness and vaccination programs led by these manufacturers across different regions, including North America, Europe, and Asia.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
